Back

Exploring the future role of glucagon-like peptide-1 receptor agonists in cardiovascular disease risk reduction

3 September 2019 (16:15 - 16:25)
Organised by:
Congress Presentation Part of: Experts on the spot: exploring new dimensions in glucagon-like peptide-1 receptor agonists and cardiovascular risk Diabetes and the Heart ESC Premium Access ESC Congress 2019

About the speaker

Photo
Doctor Benjamin Morgan Scirica

Brigham and Women's Hospital, Boston (United States of America)

3 More presentations in this session

Presentation thumbnail
New dimensions in cardiovascular risk: exploring the latest cardiovascular outcomes trials in type 2 diabetes
Doctor M. Kosiborod (Kansas City, US)
Slides Video
Presentation thumbnail
Analysing the advantages of glucagon-like peptide-1 receptor agonists/sodium-glucose cotransporter 2 inhibitors in high vs. low cardiovascular disease risk
Professor J. Deanfield (London, GB)
Slides Video
Presentation thumbnail
Connecting with the speakers: Questions and Answers
Doctor M. Kosiborod (Kansas City, US) Professor J. Deanfield (London, GB) Doctor B. Scirica (Boston, US)
Slides Video

Access the full session

Session thumbnail
Experts on the spot: exploring new dimensions in glucagon-like peptide-1 receptor agonists and cardiovascular risk

The Event

Event poster

ESC Congress 2019

3 September 2019 16:15 CET
You may be interested in
thumbnail
Congress Session
A multidisciplinary approach to type 2 diabetes, obesity, and cardiovascular diseases: current evidence and a glimpse into the future
27 August 2023
thumbnail
Congress Presentation
Exploring the preventive role of GLP-1 receptor agonists in reducing pulmonary hypertension in diabetes: a multimodal analysis
3 April 2025
thumbnail
Congress Presentation
Glucagon like peptide-1 receptor agonists and their combination with sodium-glucose cotransporter-2 inhibitors improve myocardial deformation and work index in type-2 diabetes after 12-month treatment
28 August 2020
thumbnail
Congress Presentation
Effect of oral semaglutide on CV outcomes across the vascular disease spectrum, from no vascular disease to polyvascular disease, in high-risk type 2 diabetes
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources